Monitoring the neoadjuvant therapy response in gynecological cancer patients using FDG PET

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 35, Issue 2, 2008, Pages 287-295

  Nishiyama, Yoshihiro ^a   Yamamoto, Yuka ^a   Kanenishi, Kenji ^b   Ohno, Masami ^b   Hata, Toshiyuki ^b   Kushida, Yoshio ^b   Haba, Reiji ^b   Ohkawa, Motoomi ^a  

^a KAGAWA UNIVERSITY   (Japan)

^b KAGAWA UNIVERSITY   (Japan)

Author keywords

18F FDG PET; Chemoradiotherapy; Gynecological cancer; Therapy monitoring

Indexed keywords

CARBOPLATIN; EPIRUBICIN; FLUORODEOXYGLUCOSE; NEDAPLATIN; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CALCULATION; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CLINICAL ARTICLE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; INJECTION; MONITORING; OVARY CANCER; POSITRON EMISSION TOMOGRAPHY; PREDICTION; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; TREATMENT RESPONSE; UTERUS CANCER;

ADULT; AGED; FEMALE; FLUORODEOXYGLUCOSE F18; GENITAL NEOPLASMS, FEMALE; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; OUTCOME ASSESSMENT (HEALTH CARE); POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 38349142482     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-007-0627-7     Document Type: Article

References (25)

1. Allen D, Narayan K. Managing advanced stage cervical cancer. Best Pract Res Clin Obstet Gynaecol 2005;19:591-609.
2. Mariagrazia D, Anna F, Gabriella F, Francesco F, Daniela S, Giuseppe D, et al. Preoperative chemoradiotherapy in locally advanced cervical cancer: Long-term outcome and complications. Gynecol Oncol 2005;99:S166-70.
3. Beneditti-Panici P, Greggi S, Scambia G, Amoroso M, Salerno MG, Maneschi F, et al. Long-term survival following neoadjuvant chemotherapy and radical surgery in locally advanced cervical cancer. Eur J Cancer 1998;34:341-6.
4. Schwartz PE, Rutherfold TJ, Chambers JT, Kohorn EI, Thiel RP. Neoadjuvant chemotherapy for advanced ovarian cancer: Long-term survival. Gynecol Oncol 1999;72:93-9.
5. Ansquer Y, Leblanc E, Clough K, Morice P, Dauplat J, Mathevet P, et al. Neoadjuvant chemotherapy for unresectable ovarian carcinoma: a French multicenter study. Cancer 2001;91:2329-34.
6. Park TW, Kuhn WC. Neoadjuvant chemotherapy in ovarian cancer. Expert Rev Anticancer Ther 2004;4:639-47.
7. Jurado M, Martinez-Monge R, Azinovic I, Lopez-Garcia G, Aristu J. Preoperative chemoradiation in locally advanced cervical cancer: pathologic response and a prognostic factor (abstr). Gynecol Oncol 1997;64:359.
8. Chan YM, Ng TY, Ngan HYS, Wong LC. Quality of life in women with neoadjuvant chemotherapy for advanced ovarian cancer: a prospective longitudinal study. Gynecol Oncol 2003;88:9-16.
9. Yen TC, Lai CH. Positron emission tomography in gynecological cancer. Semin Nucl Med 2006;36:93-104.
10. Westerterp M, van Westreenen HL, Reitsma JB, Hoekstra OS, Stoker J, Fockens P, et al. Esophageal cancer: CT, endoscopic US, and FDG PET for assessment of response to neoadjuvant therapy-systemic review. Radiology 2005;236:841-51.
11. 18F-FDG PET scans after neoadjuvant chemoradiation provides prognostic stratification in patients with locally advanced rectal carcinoma subsequently treated by radical surgery. J Nucl Med 2006;47:14-22.
12. Yamamoto Y, Nishiyama Y, Monden T, Sasakawa Y, Ohkawa M, Gotoh M, et al. Correlation of FDG-PET findings with histopathology in the assessment of response to induction chemoradiotherapy in non-small cell lung cancer. Eur J Nucl Med Mol Imaging 2006;33:140-7.
13. Yoshida Y, Kurokawa T, Kawahara K, Yagihara A, Tsuchida T, Okazawa H, et al. Metabolic monitoring of advanced uterine cervical cancer neoadjuvant chemotherapy by using [F-18]-fluorodeoxyglucose positron emission tomography: preliminary results in three patients. Gynecol Oncol 2004;95:597-602.
14. 18F] fluorodeoxyglucose positron emission tomography in carcinoma of the cervix: response and outcome. J Clin Oncol 2004;22:2167-71.
15. Avril N, Sassen S, Schmalfeldt B, Naehrig J, Rutke S, Weber WA, et al. Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer. J Clin Oncol 2005;23:7445-53.
16. International Federation of Gynecology and Obstetrics. Classification and staging of malignant tumors in the female pelvis: annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet 1989;28:189-92.
17. 18F]fluoro-D-glucose by direct nucleophilic exchange on a quaternary 4-aminopyridinium resin. Nucl Med Biol 1990;17:273-9.
18. Pauwels EK, McCready VR, Stoot JH, van Deurzen DF. The mechanism of accumulation of tumor-localizing pharamaceuticals. Eur J Nucl Med 1998;25:277-305.
19. Oya N, Nagata Y, Tamaki N, Takagi T, Murata R, Magata Y, et al. FDG-PET evaluation of therapeutic effects on VX2 liver tumor. J Nucl Med 1996;37:296-302.
20. Nakamoto Y, Eisbruch A, Achtyes ED, Sugawara Y, Reynolds KR, Johnston CM, et al. Prognostic value of positron emission tomography using F-18-fluorodeoxyglucose in patients with cervical cancer undergoing radiotherapy. Gynecol Oncol 2002;84:289-95.
21. Xue F, Lin LL, Dehdashti F, Miller TR, Siegel BA, Grigsby PW. F-18 fluorodeoxyglucose uptake in primary cervical cancer as an indicator of prognosis after radiation therapy. Gynecol Oncol 2006;101:147-51.
22. Reinhardt MJ, Kubota K, Yamada S, Iwata R, Yaegashi H. Assessment of cancer recurrence in residual tumors after fractionated radiotherapy: a comparison of fluorodeoxyglucose, l-methionine and thymidine. J Nucl Med 1997;38:280-7.
23. Haberkorn U, Strauss LG, Dimitrakopoupou A, Engenhart R, Oberdorfer F, Ostertag H, et al. PET studies of fluorodeoxyglucose metabolism in patients with recurrent colorectal tumors receiving radiotherapy. J Nucl Med 1991;32:1485-90.
24. 18F] FDG PET as a substitute for second-look laparotomy in patients with advanced ovarian carcinoma. Eur J Nucl Med Mol Imaging 2004;31:196-201.
25. Baum RP, Przetak C. Evaluation of therapy response in breast and ovarian cancer patients by positron emission tomography (PET). Q J Nucl Med 2001;45:257-68.